West Virginia Reaches Settlement with Juul Labs Inc.

Apr.11.2023
West Virginia Reaches Settlement with Juul Labs Inc.
West Virginia settles lawsuit with Juul for $7.9 million over allegations of unfair or fraudulent practices targeting minors.

The state of West Virginia has reached a settlement with e-cigarette manufacturer Juul Labs Inc. (hereafter referred to as Juul) over allegations that the company violated the state's consumer credit and protection laws.


Electronic cigarette manufacturer Juul has agreed to pay a $7.9 million settlement to the state. The company has been accused of engaging in unfair or deceptive practices, particularly targeted towards minors, in the manufacturing, design, sales, marketing, promotion, and distribution of e-cigarettes within the state. According to State Attorney General Patrick Morrisey, the settlement will prevent companies like Juul from adopting marketing strategies that target minors. Morrisey stated that the company was accused of deceiving consumers about the nicotine content, misrepresenting the nicotine equivalency between their products and traditional cigarettes, and underestimating the addictive risks associated with their high nicotine levels.


According to a statement from Austin Finan, Vice President of Corporate Communications for Juul Labs, this settlement represents "another step in Juul Labs' ongoing commitment to address the company's past issues.


According to Finan, the terms of the settlement agreement are similar to previous settlements and provide financial resources for further efforts to combat underage smoking and develop smoking cessation programs. This reflects the current business practices that have been implemented since the company's comprehensive relaunch in the fall of 2019. Given that West Virginia has the highest smoking rate in the United States, the company hopes that some of the funds will be directly used to reduce smoking and improve public health within the state.


According to Finan, Juul has reached a settlement with "40 states and regions, providing billions of dollars for participating states." As reported by 2FIRSTS before, Juul has already paid over $2.6 billion in settlements to different states. Finan stated, "This settlement is based on us resolving private lawsuits across the country and covers over 5,000 cases brought by approximately 10,000 plaintiffs.


According to data from the US Centers for Disease Control and Prevention (CDC), Juul e-cigarettes contain high levels of nicotine - the amount of nicotine in one Juulpod is equivalent to 20 regular cigarettes. However, the defense disagrees with this data, arguing that the total amount of nicotine in Juulpods is "equivalent to 1.72 packs (34 cigarettes).


The amount of nicotine contained in one Juulpod is equivalent to at least 20 regular cigarettes, according to a photo source provided by the Associated Press.


In 2017, 14.3% of high school students in West Virginia reported using e-cigarettes for at least one day in the past 30 days. This figure was slightly higher than the national average of 13.2%.


According to data from the 2019 National Youth Tobacco Survey, over 5 million American middle and high school students are currently using e-cigarettes, with 27.5% of high schoolers and 10.5% of middle schoolers reporting current use. Among these current e-cigarette users, 34.2% of high schoolers and 18% of middle schoolers use e-cigarettes for 20 or more days each month.


Related Reading:


2FIRSTS special: Juul settlement summary


JUUL has spent $18.2 billion in hopes of reaching a settlement. Here is a breakdown of the settlement amounts and conditions in each state.


Juul has reached a $24 million settlement agreement with Chicago.


A US district court has approved a $255m class-action settlement with Juul prior to trial.


E-cigarette company JUUL has paid a total of $1.7 billion in settlements after 34 states filed lawsuits against the company.


References:


The state of West Virginia has come to an agreement with e-cigarette company Juul.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10